Symbols

EVH

Evolent Health·NYSE

--(--)

EVH fundamentals

EVH Q4 2025 Earnings

Evolent Health (EVH) released its earnings on Feb 24, 2026: revenue was 468.72M (YoY -27.50%), beat estimates; EPS was 0.08 (YoY +500.00%), beat estimates.

Revenue / YoY

468.72M

-27.50%

EPS / YoY

0.08

+500.00%

Report date

Feb 24, 2026

EVH Earnings Call Summary for Q4,2025

Revenue Growth: 30% 2026 forecast to $2.5B, with oncology driving 65% of revenue.
Margin Targets: 7%-10% long-term margin on Performance Suite, with 2026 MER 93% (conservative reserving).
Cost Savings: $50M+ 2026 savings from AI/automation, reducing SG&A and claims processing.
New Contracts: Highmark deal ($550M+ 2026) and state expansions highlight strategic focus on enhanced Performance Suite model.
Risk Management: 10% target margin with downside protection, 7% swing potential in EBITDA based on MER performance.

Earnings

EPS

Revenue

Revenue & Expenses

EVH has released its 2025 Q4 earnings report, with revenue of 468.72M, reflecting a YoY change of -27.50%, and net profit of -429.13M, showing a YoY change of -1781.99%. The Sankey diagram below clearly presents EVH's revenue sources and cost distribution.

Key Indicators

Evolent Health (EVH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Evolent Health (EVH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Evolent Health (EVH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Evolent Health (EVH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown